Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing…
| Price | $5.11 |
|---|---|
| Market cap | $43.4M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NASDAQ |
| 52-week range | 2.61519-21.33873 |
| Beta | 1.72 |
Explore SCLX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.